Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barr syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Akari Therapeutics, Plc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

TAMPA, FLA. AND LONDON, DEC. 30, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING ANTIBODY DRUG CONJUGATES (ADCS) WITH NOVEL PAYLOADS TODAY ISSUED THE FOLLOWING LETTER TO SHAREHOLDERS FROM ITS PRESIDENT AND CHIEF EXECUTIVE OFFICER, ABIZER GASLIGHTWALA.

AKARI THERAPEUTICS ISSUES 2025 END OF YEAR LETTER TO SHAREHOLDERS

AKARI WILL EXCLUSIVELY PARTNER WITH INDUSTRY LEADER WUXI XDC FOR THIS KEY IND-ENABLING WORK AKARI WILL EXCLUSIVELY PARTNER WITH INDUSTRY LEADER WUXI XDC FOR THIS KEY IND-ENABLING WORK

AKARI THERAPEUTICS INITIATES GMP MANUFACTURING OF AKTX-101 ADC PROGRAM TO SUPPORT PHASE 1 FIRST-IN-HUMAN CLINICAL TRIAL

AKARI THERAPEUTICS RELEASES VIRTUAL INVESTOR WHAT THIS MEANS SEGMENT

NEW CASH PORTION OF OFFERING INCLUDES >20% PARTICIPATION FROM DIRECTORS, OFFICERS AND EXECUTIVE MANAGEMENT NEW CASH PORTION OF OFFERING INCLUDES >20% PARTICIPATION FROM DIRECTORS, OFFICERS AND EXECUTIVE MANAGEMENT

AKARI THERAPEUTICS ANNOUNCES $5 MILLION FINANCING, INCLUDING CONCURRENT REGISTERED DIRECT OFFERING AND PRIVATE PLACEMENT PRICED AT-MARKET

DATA HIGHLIGHTS THE ABILITY OF AKARI'S TROP2 ADC, AKTX-101, TO KILL K-RAS G12V MUTATED CANCER CELL LINES IN PRECLINICAL MODELS, POTENTIALLY ADDRESSING ONE OF THE MOST LETHAL CANCERS WITH THE LOWEST SURVIVAL RATES

AKARI THERAPEUTICS HIGHLIGHTS PRECLINICAL DATA DEMONSTRATING THERAPEUTIC POTENTIAL OF LEAD CANDIDATE, AKTX-101, FOR HARD-TO-TREAT K-RAS MUTANT PANCREATIC CANCER

ACCESS THE AKARI CEO CORNER HERE TAMPA, FLA. AND LONDON, DEC. 04, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL PAYLOADS FOR ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THE PUBLICATION OF A NEW CEO CORNER SEGMENT, NOW AVAILABLE ON THECOMPANY'S WEBSITE.

AKARI THERAPEUTICS PROVIDES CORPORATE UPDATE AND HIGHLIGHTS ITS ADC PAYLOAD INNOVATION EXPECTED TO DRIVE VALUE IN NEW CEO CORNER SEGMENT

ACCESS THE AKARI CEO CORNER HERE BOSTON AND LONDON, NOV. 25, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL PAYLOADS FOR ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THE NEXT CEO CORNER SEGMENT HAS BEEN PUBLISHED ON THE COMPANY'S WEBSITE. FOR THIS CEO CORNER SEGMENT, ABIZER GASLIGHTWALA, CEO OF AKARI, PROVIDES AN OVERVIEW OF THE COMPANY'S INNOVATION IN ADCS, HIGHLIGHTING ITS NOVEL PH1 PAYLOAD AND ITS DUAL MECHANISM OF ACTION.

AKARI THERAPEUTICS ANNOUNCES RELEASE OF THE NEXT CEO CORNER SEGMENT

MORE THAN 20 YEARS OF FINANCIAL AND OPERATIONAL LEADERSHIP IN BIOPHARMA, INCLUDING $170M+ IN CAPITAL RAISED, GLOBAL COMMERCIALIZATION EXPERIENCE, AND A PROVEN TRACK RECORD SCALING COMPANIES FROM PRECLINICAL TO CLINICAL MILESTONES MORE THAN 20 YEARS OF FINANCIAL AND OPERATIONAL LEADERSHIP IN BIOPHARMA, INCLUDING $170M+ IN CAPITAL RAISED, GLOBAL COMMERCIALIZATION EXPERIENCE, AND A PROVEN TRACK RECORD SCALING COMPANIES FROM PRECLINICAL TO CLINICAL MILESTONES

AKARI THERAPEUTICS APPOINTS BIOTECH FINANCE LEADER, KAMEEL D. FARAG AS INTERIM CHIEF FINANCIAL OFFICER

DATA PRESENTED AT THE 40 TH ANNUAL SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) MEETING THE SPLICEOSOME TARGETING PAYLOAD, PH1, DEMONSTRATES THE ABILITY TO INDUCE BOTH CANCER CELL CYTOTOXICITY AND ACTIVATION OF ANTI-TUMOR IMMUNITY THROUGH MULTIPLE MECHANISMS TREATMENT WITH A TRASTUZUMAB-PH1 ADC MONOTHERAPY DROVE MACROPHAGES TO POLARIZE INTO AN ANTI-TUMOR/INFLAMMATORY STATE AND CAUSED EXPANSION OF B CELL CLONES AND SUBSEQUENT IGM ANTIBODIES WHEN COMBINED WITH ANTI-PD1 THERAPY, ADDITIONAL EFFECTS INCLUDED EXPANSION OF GAMMA-DELTA T CELL CLONES DEMONSTRATING THAT THE COMBINED REGIMEN DRIVES INNATE, ADAPTIVE, AND HUMORAL IMMUNITY AGAINST THE TUMOR IN PRECLINICAL EXPERIMENTS, THE COMBINATION OF TRASTUZUMAB PH1 + ANTI-PD1 OUTPERFORMS THE COMBINATION OF KADCYLA  + ANTI-PD1 WITH A STATISTICALLY SIGNIFICANTLY GREATER RATE OF COMPLETE RESPONSES (74% V 42%, P

AKARI THERAPEUTICS PRESENTS PROMISING IMMUNO-ONCOLOGY DATA FOR ITS NOVEL SPLICING-TARGETED ADC PAYLOAD DRIVING IMMUNE ACTIVATION, BOTH AS SINGLE AGENT AND IN COMBINATION WITH ANTI-PD1 CHECKPOINT INHIBITORS

DATA TO BE PRESENTED AT THE 40TH ANNUAL SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) MEETING ON NOVEMBER 7TH AND 9TH DATA TO BE PRESENTED AT THE 40TH ANNUAL SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) MEETING ON NOVEMBER 7TH AND 9TH

AKARI THERAPEUTICS' ACCEPTED ABSTRACT SHOWCASING ITS NOVEL SPLICING-TARGETED ADC PAYLOAD DRIVING IMMUNE ACTIVATION NOW AVAILABLE

DR. HURVITZ IS AN INTERNATIONAL EXPERT IN ONCOLOGY AND A RECOGNIZED CLINICAL RESEARCH LEADER WITH EXTENSIVE EXPERIENCE LEADING CLINICAL TRIALS SPANNING ALL PHASES DR. HURVITZ IS AN INTERNATIONAL EXPERT IN ONCOLOGY AND A RECOGNIZED CLINICAL RESEARCH LEADER WITH EXTENSIVE EXPERIENCE LEADING CLINICAL TRIALS SPANNING ALL PHASES

AKARI THERAPEUTICS ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD AND INAUGURAL APPOINTMENT OF RENOWNED MEDICAL ONCOLOGIST, SARA A. HURVITZ, MD, FACP

Akari Therapeutics, Plc

AKTX

Price

Financial Reports

No items found.

Press Releases

Akari Therapeutics, Plc

AKTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

AKTX